Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Harrow, Inc. (HROW) has garnered strong buy ratings from analysts, indicating a positive outlook for the stock. The analysis suggests a potential upside of 52%, driving investor interest in the company.
Harrow, Inc. (HROW) has garnered attention from investors due to strong buy ratings and a potential upside of 52%. Analysts are optimistic about the company's growth prospects, highlighting its bullish technical setup and strong growth stock characteristics.
Harrow, Inc. (HROW) has garnered attention from investors due to strong buy ratings and a potential upside of 52%. Analysts are highlighting the stock's bullish technical setup, indicating it screens as a strong growth stock.
Harrow, Inc. (HROW) has garnered strong buy ratings from analysts, indicating a positive outlook for the stock. The analysis suggests a potential upside of 52%, driving investor interest in the company.
Harrow, Inc. (HROW) has garnered attention from investors due to strong buy ratings and a potential upside of 52%. Analysts are optimistic about the stock's growth prospects, indicating a bullish technical setup that may drive investor interest.
Harrow, Inc. (HROW) is gaining investor interest as it screens as a strong growth stock with a bullish technical setup. Analysts have given it strong buy ratings, indicating a potential upside of 52%.
Harrow, Inc. (HROW) has garnered strong buy ratings from analysts, indicating a positive outlook for the stock. The analysis suggests a potential upside of 52%, driving investor interest in the company.
Harrow, Inc. (HROW) is gaining investor interest due to strong buy ratings and a potential upside of 52%. Analysts are optimistic about the stock's growth prospects, highlighting its bullish technical setup.
Harrow's Iheezo Cuts Eye-Injection Discomfort by More Than Half
Harrow Adds Another Piece To Ophthalmology Strategy
These Analysts Revise Their Forecasts On Harrow Following Q4 Results
Why Is Eye-Disease-Focused Harrow Stock Falling Today?